Videos / Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD

Product Explainer

Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD

Description

In this Product Explainer, Respiratory Physician Dr Martin MacDonald explains the role of single inhaler triple therapy containing fluticasone furoate/umeclidinium/vilanterol for the management of moderate to severe COPD (5 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-VID-230011 Approved October 2023.

NEXT LIVE Webcast

Days

Hours

Minutes

Seconds

Dr Gabby Mahoney

Eczema Management Practical Tips

Prof Deborah Bateson

Oral Contraception Updates

Prof Genie Pedagogos, Prof Richard MacIsaac & A/Prof Ralph Audehm

Panel Discussion on GLP1s for Chronic Kidney Disease in Type 2 Diabetes

Prof Clara Chow AM

COVID and the Heart – Short & Long-Term Impacts and Risks

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

28 October 2025

expert

A/Prof Martin MacDonald

Respiratory Physician, Monash Medical Centre; Head of Unit, Respiratory and General Medicine, Jessie McPherson Private Hospital

Product Explainer

Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD